28 January 2020, London. EMMAC Life Sciences Group, Europe’s leading independent cannabis company, announces that the manuscript “Cannabidiol for Viral Diseases: Hype or Hope?” has been published in the latest edition of ‘Cannabis and Cannabinoid Research’, the only peer-reviewed journal dedicated to the scientific, medical and psychosocial exploration of clinical cannabis, cannabinoids and the endocannabinoid system, and the official journal of the International Cannabinoid Research Society (ICRS) and the International Association for Cannabis as Medicine (IACM).
The manuscript is part of EMMAC’s research collaboration with University of Insubria, Italy, forged to deliver a long-term comprehensive research programme designed to inform and shape the future of the medical cannabis therapeutic industry. The programme aims to investigate mechanisms of action of cannabis-based medicinal products related to several clinical applications including immune-related diseases.
The manuscript is a positioning paper on the expected role of cannabidiol (CBD) in recurrent viral diseases. The effect of cannabidiol as an antiviral or to treat viral diseases has received limited attention to date, despite the growing number of claims that CBD could be used for the treatment of viral infection-related conditions. The paper presents a critical evaluation of the current scientific knowledge of CBD in viral diseases and shares recommendations for future research directions. Whilst preclinical studies suggest the potential effectiveness of CBD to treat viral diseases such as hepatitis C and Kaposi sarcoma, clinical evidence remains limited, with only anecdotal experiences of CBD use; these anecdotal experiences however, could be used in some instances to inform the direction of further clinical trials to assess the conditions associated with viral infections.
Dr Barbara Pacchetti, Chief Scientific Officer at EMMAC, commented: “At EMMAC we believe the growth of medical cannabis must be underpinned by the most robust science, and we aim to publish and present all research through peer-reviewed journal publications and recognised international conferences. We look forward to sharing more research as EMMAC continues to work with the University of Insubria and other leading European institutions to advance the industry’s understanding of the medical benefits of cannabis.”
EMMAC Life Sciences Group is Europe’s leading independent cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, EMMAC’s
vision is to bring the life-enhancing potential of cannabis to the people who need it.
About University of Insubria, Italy
The Center for Research in Medical Pharmacology at the University of Insubria is an international leading center in the emerging field of neuroimmune pharmacology, a young but rapidly growing discipline encompassing interdisciplinary research in pharmacology, immunology and neuroscience, with the overarching goal to identify novel therapeutic approaches thanks to the investigations of the neuroimmune network. Basic and clinical research focus on the pathophysiology and therapeutics of major diseases such as multiple sclerosis, Parkinson’s disease, atherosclerosis and other immunoinflammatory-based disease. Clinical pharmacology, pharmacogenetics, pharmacoepidemiology and pharmacovigilance are included among the interests and approaches of the Center
All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Ltd. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.
Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences Ltd assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.